By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

News Junction

Notification Show More
Font ResizerAa
  • Home
  • World News
    World NewsShow More
    A Russian delegation has arrived in Istanbul for Ukraine talks. It doesn’t include Putin
    A Russian delegation has arrived in Istanbul for Ukraine talks. It doesn’t include Putin
    May 15, 2025
    Once ‘dead’ thrusters on the farthest spacecraft from Earth are in action again
    Once ‘dead’ thrusters on the farthest spacecraft from Earth are in action again
    May 15, 2025
    ‘Don’t know what to do’: Johor Bahru’s heritage businesses near RTS station grapple with rising rents, inflation
    ‘Don’t know what to do’: Johor Bahru’s heritage businesses near RTS station grapple with rising rents, inflation
    May 15, 2025
    Jurors view ‘Freak off’ images too graphic to be shown to public
    Jurors view ‘Freak off’ images too graphic to be shown to public
    May 15, 2025
    Gaza hospital attack: Analysis contradicts Israel’s evidence justifying airstrike | World News
    Gaza hospital attack: Analysis contradicts Israel’s evidence justifying airstrike | World News
    May 15, 2025
  • Business
    BusinessShow More
    Ukraine blows up bridges to consolidate its positions in Russia
    Ukraine blows up bridges to consolidate its positions in Russia
    August 18, 2024
    Commentary: AI phones from Google and Apple will erode trust in everything
    Commentary: AI phones from Google and Apple will erode trust in everything
    August 18, 2024
    The most famous Indian Dishes – Insights Success
    The most famous Indian Dishes – Insights Success
    August 18, 2024
    Life on the road as a female long rides cyclist
    Life on the road as a female long rides cyclist
    August 18, 2024
    UK inflation rises to 2.2%
    UK inflation rises to 2.2%
    August 18, 2024
  • Cryptocurrency
    CryptocurrencyShow More
    Senate removes Trump provisions in push to pass stablecoin bill
    Senate removes Trump provisions in push to pass stablecoin bill
    May 15, 2025
    MOODENG price drops 14% to alt=
    MOODENG price drops 14% to $0.2613 after 703% weekly rally
    May 15, 2025
    Bitwise CIO bats for diversified crypto investment, compares Bitcoin to Google
    Bitwise CIO bats for diversified crypto investment, compares Bitcoin to Google
    May 15, 2025
    The Role of Altcoins in 2025’s Crypto Market
    The Role of Altcoins in 2025’s Crypto Market
    May 15, 2025
    Bitcoin Spread Oscillator Signals Growing Altcoin Momentum – Altseason Entry Signal?
    Bitcoin Spread Oscillator Signals Growing Altcoin Momentum – Altseason Entry Signal?
    May 15, 2025
  • Technology
    TechnologyShow More
    How to Improve Your Spotify Recommendations
    How to Improve Your Spotify Recommendations
    August 18, 2024
    X says it’s closing operations in Brazil
    X says it’s closing operations in Brazil
    August 18, 2024
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    August 18, 2024
    Scientists Want to See Videos of Your Cat for a New Study
    Scientists Want to See Videos of Your Cat for a New Study
    August 18, 2024
    OpenAI’s new voice mode let me talk with my phone, not to it
    OpenAI’s new voice mode let me talk with my phone, not to it
    August 18, 2024
  • Entertainment
  • Sports News
  • People
  • Trend
Reading: It’s Finally Over for Aduhelm, the Sketchy Alzheimer’s Drug Everyone Hated
Share
Font ResizerAa

News Junction

  • World News
  • Business
  • Technology
  • Cryptocurrency
  • Trend
  • Entertainment
Search
  • Recent Headlines in Entertainment, World News, and Cryptocurrency – NewsJunction
  • World News
  • Business
  • Cryptocurrency
  • Technology
  • Entertainment
  • Sports News
  • People
  • Trend
Have an existing account? Sign In
Follow US
News Junction > Blog > Technology > It’s Finally Over for Aduhelm, the Sketchy Alzheimer’s Drug Everyone Hated
It’s Finally Over for Aduhelm, the Sketchy Alzheimer’s Drug Everyone Hated
Technology

It’s Finally Over for Aduhelm, the Sketchy Alzheimer’s Drug Everyone Hated

Published February 2, 2024
Share
6 Min Read
SHARE

Biogen is abandoning its lackluster Alzheimer’s disease drug, Aduhelm. The Massachusetts-based company announced Wednesday that it is pulling the medication from the market following poor sales and controversy over its approval by the Food and Drug Administration in 2021. The company says it is only doing so to “reprioritize” its resources toward its other, less contentious Alzheimer’s treatments, such as Leqembi.

Lisa Frankenstein’s Crew on Casting the Right Stars

Adulhelm was developed by Biogen in conjunction with the Japanese pharmaceutical company Eisai, after being licensed from the company Neurimmune. It’s made with the active ingredient aducanumab, a lab-made antibody designed to target the misfolded version of the protein amyloid beta. In people with Alzheimer’s, this rogue amyloid beta builds up in the brain, eventually turning into damaging clumps called plaques. Because aducanumab can break down plaque in the lab, scientists hoped that it could slow or even reverse the worsening of Alzheimer’s symptoms.

The trouble is that Aduhelm never really seemed to work as intended. In 2019, Biogen ended its Phase III research early after an independent panel of experts monitoring the data determined that it likely wouldn’t meet the pre-established goals of the trials, which were to noticeably slow down patients’ loss of cognitive function. About six months later, however, the company suddenly changed course, announcing that its updated reanalysis actually did find enough evidence of the drug’s efficacy and that it would submit the drug for formal FDA approval.

But other experts didn’t buy what Biogen was selling. In November 2020, an outside advisory committee assembled by the FDA largely recommended that the FDA not approve the drug. The FDA rarely disagrees with these recommendations, but it did just that in June 2021, when it granted Aduhelm accelerated approval, a special category that requires less rigorous evidence of a drug’s effectiveness (in exchange, companies are required to run more clinical trials and eventually present solid proof of the drug’s value). The company raised further eyebrows when it announced that the drug’s list price would be $56,000 a year.

While some patient advocates did laud the drug’s approval, the reaction from the scientific community was largely negative, and swiftly so. Several experts on the FDA’s advisory committee resigned in protest, while many doctors vowed that they would not prescribe the drug to their patients. By the end of the month, the media outlet STAT News uncovered evidence of an unusually friendly relationship between top Biogen employees and FDA officials, which prompted a Congressional investigation into the matter. This investigation eventually found that the FDA’s approval process of Aduhelm was “rife with irregularities.”

But perhaps the final nail in the coffin came in April 2022, when Medicare formally enacted a policy that would severely limit its coverage of the drug and other Alzheimer’s drugs with accelerated approval until such treatments showed clear evidence of working. Around the same time, Eisai washed its hands of the whole thing and ceded complete control of the drug to Biogen.

In the wake of all this, Aduhelm has failed to generate any major sales, even after the company lowered the list price by half. According to Biogen, there are only about 2,500 people taking the drug currently, scattered across the company’s clinical, commercial, and global access programs.

Biogen will not only pull Aduhelm from the market but also terminate its remaining clinical clinical trials of it. In its announcement of the decision to fully can Aduhelm, the company denied that the move was related to “any safety or efficacy concerns.” And it claims that most of the resources dedicated to supporting the drug will simply be relocated to other parts of its Alzheimer’s development program.

“We have gained significant insight from the development of ADUHELM and will carry this forward as we continue our pioneering work in Alzheimer’s disease,” said Priya Singhal, head of development at Biogen, in the company’s announcement.

Biogen has seen more success with its second-generation anti-amyloid drug Leqembi. Unlike Aduhelm, this drug was found to clearly meet the goals of its Phase III trials in slowing people’s rate of cognitive decline. Scientists are still arguing over whether this modest reduction is really noticeable in patients’ everyday life, but Leqembi’s full FDA approval last year was generally seen in a much more positive light. And it’s possible that future similar treatments or other interventions really will lead to substantial improvements in Alzheimer’s care someday soon.

If so, then Aduhelm might just end up becoming a messy footnote in an otherwise hopeful story.

#Finally #Aduhelm #Sketchy #Alzheimers #Drug #Hated

TAGGED:Accelerated approvalAducanumabAduhelmAlzheimer's diseaseAlzheimersBiogendrugEisaiFinallyFood and Drug AdministrationGizmodohatedhealthLecanemabLeqembiMedicalNeurimmunePharmaPriya SinghalSketchySketchy AlzheimerSpinal muscular atrophy
Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Affordable E-Bike Ranges : e feel Affordable E-Bike Ranges : e feel
Next Article Real Madrid reclaim top spot as Joselu seals win at Getafe Real Madrid reclaim top spot as Joselu seals win at Getafe
- Advertisement -

Latest Post

A Russian delegation has arrived in Istanbul for Ukraine talks. It doesn’t include Putin
A Russian delegation has arrived in Istanbul for Ukraine talks. It doesn’t include Putin
World News
Senate removes Trump provisions in push to pass stablecoin bill
Senate removes Trump provisions in push to pass stablecoin bill
Cryptocurrency
Once ‘dead’ thrusters on the farthest spacecraft from Earth are in action again
Once ‘dead’ thrusters on the farthest spacecraft from Earth are in action again
World News
MOODENG price drops 14% to alt=
MOODENG price drops 14% to $0.2613 after 703% weekly rally
Cryptocurrency
Bitwise CIO bats for diversified crypto investment, compares Bitcoin to Google
Bitwise CIO bats for diversified crypto investment, compares Bitcoin to Google
Cryptocurrency
The Role of Altcoins in 2025’s Crypto Market
The Role of Altcoins in 2025’s Crypto Market
Cryptocurrency
- Advertisement -

You Might Also Like

Security flaw at Christie’s exposed location data of artwork owners sought to sell
Technology

Security flaw at Christie’s exposed location data of artwork owners sought to sell

August 21, 2023
UK launches antitrust probe into planned B Vodafone / Three merger
Technology

UK launches antitrust probe into planned $19B Vodafone / Three merger

January 26, 2024
TikTok now lets brands buy ads that appear in the app’s search results
Technology

TikTok now lets brands buy ads that appear in the app’s search results

August 22, 2023
John Wick’s Future Begins With a New TV Series
Technology

John Wick’s Future Begins With a New TV Series

August 5, 2024

About Us

NEWS JUNCTION (NewsJunction.xyz) Your trusted destination for global news. Stay informed with our timely and accurate reporting on diverse topics, including politics, technology, science, entertainment, sports, and more. Count on us for unbiased and reliable updates at your fingertips.

Quick Link

  • About
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Contact

Top Categories

  • World News
  • Business
  • Technology
  • Entertainment
  • Cryptocurrency
  • Sports News
  • Trend
  • People

Subscribe

Subscribe to our newsletter to get our newest articles instantly!

    © 2023 News Junction.
    • Blog
    • Advertise
    • Contact
    Welcome Back!

    Sign in to your account

    Username or Email Address
    Password

    Lost your password?